CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 233 filers reported holding CLOVIS ONCOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $41,000 | -97.7% | 6,100 | -76.3% | 0.00% | -100.0% |
| Q4 2017 | $1,748,000 | -22.6% | 25,700 | -6.2% | 0.00% | -40.0% |
| Q3 2017 | $2,258,000 | -47.9% | 27,400 | -40.8% | 0.01% | -50.0% |
| Q2 2017 | $4,335,000 | +35.3% | 46,300 | -8.0% | 0.01% | +25.0% |
| Q1 2017 | $3,203,000 | +75.4% | 50,300 | +22.4% | 0.01% | +14.3% |
| Q4 2016 | $1,826,000 | +17.0% | 41,100 | -5.1% | 0.01% | +16.7% |
| Q3 2016 | $1,561,000 | +247.7% | 43,300 | +32.4% | 0.01% | +200.0% |
| Q2 2016 | $449,000 | -11.8% | 32,700 | +23.4% | 0.00% | 0.0% |
| Q1 2016 | $509,000 | -79.6% | 26,500 | -62.8% | 0.00% | -83.3% |
| Q4 2015 | $2,495,000 | -56.7% | 71,292 | +13.7% | 0.01% | -50.0% |
| Q3 2015 | $5,765,000 | +645.8% | 62,692 | +612.4% | 0.02% | +700.0% |
| Q2 2015 | $773,000 | -34.1% | 8,800 | -44.3% | 0.00% | -25.0% |
| Q1 2015 | $1,173,000 | – | 15,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $18,097,419,000 | 17.62% |
| Boxer Capital, LLC | 850,000 | $37,757,000 | 14.60% |
| Consonance Capital Management LP | 2,730,887 | $121,306,000 | 13.32% |
| Palo Alto Investors LP | 3,804,088 | $168,978,000 | 9.64% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 298,982 | $13,281,000 | 8.01% |
| Redmile Group, LLC | 1,620,355 | $71,976,000 | 6.20% |
| Crosspoint Capital Strategies, LLC | 84,076 | $3,735,000 | 3.32% |
| Ghost Tree Capital, LLC | 220,000 | $9,772,000 | 2.35% |
| PointState Capital LP | 3,171,978 | $140,899,000 | 2.03% |
| NEA Management Company, LLC | 1,139,890 | $50,634,000 | 2.01% |